Epicardial Adipose Tissue: Functions and Health Risks

Epicardial adipose tissue is a thin layer of fat that sits directly on the surface of the heart, sandwiched between the heart muscle and the protective sac called the pericardium. In healthy conditions, it serves the heart by supplying fuel, generating heat, and cushioning the coronary arteries. But when it grows too large or becomes inflamed, it can turn from an ally into a threat, releasing inflammatory chemicals straight into the heart and contributing to conditions ranging from coronary artery disease to heart failure and irregular heart rhythms. What makes this fat depot unusual, and increasingly interesting to researchers, is that it can communicate with the heart muscle without ever entering the general bloodstream.

Where Epicardial Fat Sits and Why Its Location Matters

Unlike the fat around your waist or thighs, epicardial fat is a visceral fat depot positioned with no physical barrier between it and the heart muscle itself.¹ It shares a blood supply with the underlying heart tissue, which means any chemical signals it produces have an almost immediate route into the cardiac muscle and coronary arteries. This is different from pericardial adipose tissue, which sits outside the pericardial sac and influences cardiovascular health more through systemic, whole-body effects.² The distinction matters clinically because epicardial fat’s direct contact with the heart gives it outsized local influence relative to its small volume.

Developmental research has traced the origin of this fat to the epicardium itself, the thin outer layer of the heart. During development, certain epicardial cells undergo a transformation and become fat cells under the influence of specific molecular signals.³ This shared lineage with heart tissue may help explain why epicardial fat is so metabolically active and so tightly integrated with cardiac function.

The Protective Side of Epicardial Fat

When functioning normally, epicardial fat does real work for the heart. It acts as an energy reservoir, supplying fatty acids that heart muscle cells burn as fuel. It also supports thermoregulation, helping to keep the heart at a stable temperature through a process similar to what brown fat does elsewhere in the body.⁴ In fact, healthy epicardial fat has characteristics resembling brown fat, meaning it can burn calories to produce heat rather than simply storing energy.⁵ This thermogenic ability is thought to protect the heart muscle and coronary arteries from cold stress and metabolic fluctuations.

Epicardial fat also provides mechanical cushioning for the coronary arteries, buffering them against the constant twisting and compression that comes with every heartbeat. In a healthy person, these functions make epicardial fat a useful and even essential part of cardiac anatomy.

How Epicardial Fat Turns Harmful

The trouble begins when epicardial fat loses its brown-fat-like characteristics and starts behaving more like inflammatory belly fat. This shift tends to happen with aging and in the presence of chronic conditions like obesity, diabetes, and metabolic syndrome. As the fat depot expands and undergoes what researchers call phenotypic switching, it gradually loses its heat-generating function and begins producing inflammatory molecules instead.⁶

The way epicardial fat delivers these inflammatory signals is what makes it especially dangerous. Because no barrier separates it from the heart, it can release chemicals directly into the cardiac muscle through a process called paracrine signaling, where molecules diffuse from one cell to its neighbor. It can also secrete these chemicals into the tiny blood vessels that feed the walls of the coronary arteries, a route that researchers have termed “vasocrine” signaling.⁷ These signaling molecules move from the fat into the coronary artery wall, promoting the buildup of plaque from the outside in.⁸ This is fundamentally different from how cholesterol-laden plaques typically form through the bloodstream, and it helps explain why some people develop coronary artery disease in ways that traditional risk factors alone do not predict.

Coronary Artery Disease and Plaque Vulnerability

The relationship between epicardial fat and coronary artery disease has been documented across multiple imaging studies. People with thicker epicardial fat tend to have more lipid-rich, vulnerable plaques in their coronary arteries. One study using specialized intravascular imaging found that patients with thicker epicardial fat had significantly higher lipid content in their coronary plaques, and that this fat thickness independently predicted the presence of high-risk plaques even after accounting for age, cholesterol levels, and overall plaque burden.⁹

Interestingly, the picture gets more complicated in people whose coronary arteries look fairly normal on standard imaging. In patients without major blockages, higher epicardial fat volume was associated with markers of inflammation and with a specific type of plaque remodeling that can make even small plaques prone to rupture.¹⁰ A follow-up study tracking plaque progression over time found that patients with high epicardial fat volume showed an increase in the proportion of vulnerable, low-density plaque even as their overall plaque volume appeared stable or slightly decreased.¹¹ In other words, the fat was not just associated with more plaque; it was associated with more dangerous plaque.

Atrial Fibrillation and Epicardial Fat

The link between epicardial fat and atrial fibrillation is one of the more active areas of research. The left atrium, where most atrial fibrillation originates, is surrounded by epicardial fat, and the inflammatory signals from that fat appear to drive structural changes in the atrial muscle. A study examining tissue samples from patients undergoing heart surgery found that the epicardial fat surrounding the left atrium was significantly remodeled with fibrosis and contained elevated levels of inflammatory molecules. Those changes were directly associated with the degree of scarring in the underlying atrial muscle, which is the structural substrate that enables and sustains atrial fibrillation.¹²

Cardiac MRI studies have reinforced this connection, showing that epicardial fat volume and left atrial size are both significant markers of atrial fibrillation, with particularly strong correlations in patients who already have persistent atrial fibrillation.¹³ The mechanism seems to run in one direction: the fat promotes fibrosis in the atrial wall, and that fibrosis disrupts the electrical signals that keep the heart beating in rhythm.

Heart Failure with Preserved Ejection Fraction

One of the most intriguing connections involves heart failure with preserved ejection fraction, or HFpEF, a condition in which the heart pumps blood adequately but fills inefficiently. HFpEF is common in older, overweight adults and has long been difficult to explain. Epicardial fat may be part of the answer. Excess fat around the heart appears to contribute to HFpEF through two routes. First, the fat can physically compress the heart, creating a constriction-like effect that limits how much the chambers can expand to fill with blood. Second, the inflammatory and fibrotic chemicals it releases can stiffen the heart muscle itself.¹⁴

A study of patients with the obese form of HFpEF found that those with more epicardial fat had worse filling pressures at rest and during exercise, more severe pulmonary hypertension, greater pericardial restraint, and poorer exercise capacity compared with patients who had less epicardial fat.¹⁵ This finding has helped shape a growing understanding that obesity-related HFpEF may be a condition fundamentally driven by cardiac fat rather than by high blood pressure or aging alone.

Metabolic Links Beyond the Heart

Epicardial fat does not exist in isolation from the body’s broader metabolic state. It is strongly tied to insulin resistance, which is the core feature of type 2 diabetes and metabolic syndrome. Studies using precise metabolic testing have shown that epicardial fat thickness correlates with how poorly the body processes sugar, independent of overall body weight.¹⁶ This relationship holds even in people who are not obese. In one study of non-obese individuals without metabolic syndrome, those with higher epicardial fat volumes had roughly two and a half times the odds of being insulin resistant after adjusting for age, sex, and BMI, and about twice the odds of having coronary artery disease.¹⁷

This is a crucial finding because it suggests that epicardial fat volume may be a better indicator of cardiometabolic risk than traditional measures like BMI or waist circumference, especially in people who appear metabolically healthy on the surface. Someone at a normal weight can still carry excess epicardial fat and face elevated risk.

How Epicardial Fat Is Measured

Epicardial fat can be measured using echocardiography, CT scanning, or cardiac MRI. Each approach has tradeoffs. Echocardiography is widely available and inexpensive but provides only a thickness measurement at a single point, which may not capture the full picture. CT and MRI offer volumetric measurements that account for the fat’s uneven distribution around the heart and are more reproducible.¹⁸

CT has an additional advantage: it can assess not just the volume of epicardial fat but also its density. Inflamed fat is denser than healthy fat because inflammation causes changes in water content and cellular composition. A measurement called the fat attenuation index captures this density shift and is emerging as a potentially more informative marker than volume alone, because it reflects the fat’s inflammatory state rather than just its size.¹⁹ In one long-term study following asymptomatic adults for over a decade, both increased epicardial fat volume and decreased fat density (indicating inflammation) independently predicted major adverse cardiovascular events. Risk was highest in people who had both an epicardial fat volume above about 113 cubic centimeters and a coronary calcium score above 100.²⁰

These measurements are not yet part of routine clinical care. However, because many people already get CT scans for coronary calcium scoring, researchers are exploring whether epicardial fat data could be extracted from those same scans at no extra cost. Early results using artificial intelligence to automatically assess epicardial fat from standard calcium-score CT scans have been mixed. Traditional measures like volume and average density on their own have offered only modest predictive power, though more sophisticated AI-derived features may perform better.²¹ In chronic heart failure, epicardial fat volume measured by cardiac MRI has shown more promising accuracy for predicting outcomes over one to three years.²²

What Can Reduce Epicardial Fat

Given the health risks, a natural question is whether epicardial fat can be shrunk. The answer is yes, but not all approaches work equally well. A systematic review and meta-analysis that pooled multiple intervention studies found that diet and bariatric surgery significantly reduced epicardial fat, while exercise alone produced less consistent results in the earlier evidence.²³ A later and larger meta-analysis, however, found that exercise training did significantly reduce epicardial fat compared with no intervention, and confirmed that diet, bariatric surgery, and pharmaceutical treatments were also effective.²⁴ The discrepancy likely reflects the larger number of exercise studies available by the time the later review was published.

One curious finding from bariatric surgery research is that epicardial fat appears relatively resistant to reduction compared with other fat depots. A study comparing bariatric surgery with exercise found that while surgery produced dramatically greater reductions in abdominal visceral fat and pericardial fat, the reduction in epicardial fat specifically was actually slightly less with surgery than with exercise.²⁵ The reasons for this relative preservation are not fully understood, but it may reflect epicardial fat’s unique metabolic role and blood supply.

On the pharmaceutical side, two classes of diabetes drugs have attracted the most attention. GLP-1 receptor agonists (the drug class that includes semaglutide and liraglutide) and SGLT2 inhibitors (like empagliflozin and dapagliflozin) both reduce epicardial fat, and they appear to do so through mechanisms beyond simple weight loss.²⁶ A meta-analysis found that all three major cardiometabolic drug classes studied (GLP-1 receptor agonists, SGLT2 inhibitors, and statins) significantly reduced epicardial fat, with GLP-1 receptor agonists showing the largest effect.²⁷ However, a separate network meta-analysis that directly compared the drug classes ranked SGLT2 inhibitors as more effective than GLP-1 agonists for epicardial fat reduction.²⁸ The disagreement between these two analyses likely comes down to differences in the studies they included and how they defined their comparisons, but both confirm that these drug classes meaningfully shrink cardiac fat.

Statins have a somewhat different story. While they produce only a modest reduction in epicardial fat volume, they appear to change the fat’s density in ways that suggest reduced inflammation, and this effect seems to be independent of their cholesterol-lowering action.²⁹ This is a useful reminder that shrinking the fat is not the only goal; calming its inflammatory activity may matter just as much.

Sex Differences in Epicardial Fat Behavior

One underappreciated aspect of epicardial fat is that it seems to behave quite differently in men and women. A study that examined epicardial fat cell sizes in surgical patients found that in men, BMI and age were independently predictive of fat cell size, and epicardial fat cell sizes were correlated with epicardial fat volume. In women, none of those relationships held. No clinical measurements were useful surrogates for epicardial fat cell size in women, whereas BMI, age, and epicardial fat volume were predictive in men.³⁰ This disconnect means that using the same clinical measures to estimate epicardial fat risk in both sexes could lead to underestimating risk in women. The biology of this sex difference remains unclear, but it fits with a broader pattern in cardiology where female-specific risk factors are often less well captured by standard tools.

Studying Epicardial Fat Up Close

Much of what we know about epicardial fat’s inflammatory behavior comes from tissue samples collected during open-heart surgery. During coronary artery bypass or valve procedures, surgeons can collect small samples of epicardial fat from the surface of the heart before placing the patient on a heart-lung bypass machine. These samples are then compared with fat taken from outside the pericardium and from beneath the skin of the chest wall, providing a direct look at how the three fat depots differ in their molecular profiles.³¹ This kind of translational research has been essential for confirming that the inflammatory signals detected in imaging studies actually correspond to real molecular changes in the fat tissue itself, and for identifying specific molecules that could eventually become drug targets.

The challenge with surgical studies is inherent selection bias: the patients donating these tissue samples are already sick enough to need heart surgery. Researchers are working to bridge this gap using more detailed imaging markers like the fat attenuation index, which can approximate the inflammatory state of epicardial fat without requiring surgery. Whether these imaging-based measures can eventually replace tissue analysis for clinical decision-making is an open question, but the trajectory of the research suggests that epicardial fat assessment, in some form, will become a standard part of cardiac risk evaluation within the next decade.